Cover Image
市場調查報告書

癌症/腫瘤分析的全球市場的預測 ∼2021年:基因學、蛋白質體學、代謝體學、表觀遺傳學

Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray) - Forecast to 2021

出版商 MarketsandMarkets 商品編碼 408032
出版日期 內容資訊 英文 156 Pages
訂單完成後即時交付
價格
Back to Top
癌症/腫瘤分析的全球市場的預測 ∼2021年:基因學、蛋白質體學、代謝體學、表觀遺傳學 Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, qPCR, In-situ Hybridization, Microarray) - Forecast to 2021
出版日期: 2018年01月02日 內容資訊: 英文 156 Pages
簡介

全球癌症/腫瘤分析的市場在預測期間內,用19.1%的年複合成長率發展,從2016年的258億2000萬美元,2021年618億7000萬美元的規模成長。癌症的病例數的全球的增加和生物標記的效用的提高,癌症研究資金的可用性等的要素促進該市場的成長。

本報告提供全球癌症/腫瘤分析的市場調查,市場定義和概要,市場成長的各種影響因素及市場機會分析,各用途、手法、技術、地區/主要國家的趨勢與市場規模的變化與預測,競爭環境,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場概要
  • 各地區、技術的市場成果
  • 市場規模的成果、預測:各手法
  • 市場規模的成果、預測:各用途
  • 各地區的成長機會

第5章 癌症/腫瘤分析的全球市場:概要

  • 簡介
  • 市場動態
    • 促進要素
    • 阻礙要素
    • 機會
    • 課題

第6章 癌症/腫瘤分析的全球市場:各用途

  • 簡介
  • 個人化醫療
  • 診斷
  • 生物標誌物的發現
  • 預後診斷
  • 研究

第7章 癌症/腫瘤分析的全球市場:各手法

  • 簡介
  • 基因學
  • 蛋白質體學
  • 表觀遺傳學
  • 代謝體學

第8章 癌症/腫瘤分析的全球市場:各技術

  • 簡介
  • 次世代定序 (NGS)
  • 定量聚合酵素鏈鎖反應 (QPCR)
  • 免疫組織化學 (ICH)
  • 原位雜合反應 (ISH)
    • 螢光原位雜交計數系統 (FISH)
    • 顯象原位雜合反應 (CISH)
  • 微陣列

第9章 癌症/腫瘤分析的全球市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
    • 中國
    • 日本
    • 其他
  • 其他地區

第10章 競爭環境

  • 概要
  • 市場佔有率的相爭
  • 產品的投入
  • 協定、聯盟、合作
  • 收購
  • 其他

第11章 企業簡介

  • 簡介
  • ILLUMINA, INC.
  • QIAGEN N.V.
  • NEOGENOMICS LABORATORIES, INC.
  • HTG MOLECULAR DIAGNOSTICS, INC.
  • GENOMIC HEALTH INC.
  • CARIS LIFE SCIENCES
  • HELOMICS CORPORATION
  • NANOSTRING TECHNOLOGIES, INC.
  • OXFORD GENE TECHNOLOGY
  • RIBOMED BIOTECHNOLOGIES, INC.
    • 簡介
    • 產品與服務
    • 策略
    • 分析師的見解等

第12章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MD 4803

"The global cancer/tumor profiling market is projected to grow at a CAGR of 10.7%."

Global cancer/tumor profiling market is projected to reach USD 8.74 billion in 2022 from USD 5.26 billion in 2017 at CAGR of 10.7%. The cancer/tumor profiling market is primarily driven by the increasing number of cancer cases, growing utility of biomarkers in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

"The immunoassays segment is expected to account for the largest share in 2017."

On the basis of technology, the global cancer/tumor profiling market is broadly divided into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. In 2017, the immunoassays segment is expected to account for the largest share of the cancer/tumor profiling technologies market. The high sensitivity and cost-effectiveness of these techniques as well as technological advancements in these immunoassays tests are factors that are expected to propel the growth of this market in the coming years. Furthermore, the hybridization technology is again divided on the basis of type which includes PCR, in-situ hybridization, and microarrays. The PCR segment is expected to account for the largest market share of hybridization technology in 2017. PCR is one of the most widely used technologies in the diagnostics market. This is primarily due to its ease of use, cost-effectiveness, quick turnaround time (4 to 6 hours), and easy availability of kits and reagents.

"The clinical application segment is expected to account for the largest share in 2017."

Based on application, the cancer/tumor profiling market is categorized into clinical application, and research application. In 2017, the clinical application segment is expected to account for the largest share of the cancer/tumor profiling market. Technological advancements and the need for early diagnosis are further aiding market growth in this segment.

"North America is expected to account for the largest share in 2017."

Among the four regions, North America is expected to account for the largest share of the cancer/tumor profiling market in 2017, followed by Europe, APAC, and the RoW. The large share of the North American market is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.

Break-up Profile of Primaries:

  • By Company Type- Tier 1-45%, Tier 2-34% and Tier 3-21%
  • By Designation- C-level-14%, D-level-10% and Others-76%
  • By Region- North America-40%, Europe-32%, Asia Pacific-20%, and RoW-8%

The cancer/tumor profiling market is dominated by established players such as Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US).

Research Coverage:

The cancer/tumor profiling market in this report is segmented by cancer type, application, technology, and region. The study tracks and analyzes competitive developments such as product launches, collaborations, agreements, partnerships, and acquisitions, and profiles key players and core competencies in the cancer/tumor profiling market.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes the market by function, solution, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global cancer/tumor profiling market
  • Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for global cancer/tumor profiling products across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global cancer/tumor profiling market
  • Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global cancer/tumor profiling market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
  • 1.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
      • 2.2.2.1. Key industry insights
    • 2.2.3. ASSUMPTIONS FOR THE STUDY
  • 2.3. MACROECONOMIC FACTOR ANALYSIS
    • 2.3.1. INTRODUCTION
    • 2.3.2. DEMAND-SIDE ANALYSIS
      • 2.3.2.1. Healthcare expenditure pattern
    • 2.3.3. SUPPLY-SIDE ANALYSIS
      • 2.3.3.1. Number of new product launches

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. CANCER/TUMOR PROFILING: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (2017)
  • 4.3. CANCER/TUMOR PROFILING MARKET, BY APPLICATION
  • 4.4. CANCER/TUMOR PROFILING MARKET, BY HYBRIDIZATION TECHNOLOGY
  • 4.5. GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing number of new cancer cases
      • 5.2.1.2. Increasing utility of biomarkers in tumor profiling
      • 5.2.1.3. Availability of funding for cancer research
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High capital investments and low benefit ratio for biomarkers
      • 5.2.2.2. Lack of skilled professionals and infrastructure
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Point-of-care diagnostic tests
      • 5.2.3.2. Increasing demand for personalized medicine
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Unclear regulatory and reimbursement scenario

6. CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

  • 6.1. INTRODUCTION
  • 6.2. IMMUNOASSAYS
  • 6.3. HYBRIDIZATION
    • 6.3.1. PCR
    • 6.3.2. IN SITU HYBRIDIZATION (ISH)
    • 6.3.3. DNA/RNA MICROARRAY
  • 6.4. NEXT GENERATION SEQUENCING
  • 6.5. MASS SPECTROMETRY
  • 6.6. OTHER TECHNOLOGIES

7. CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE

  • 7.1. INTRODUCTION
  • 7.2. BREAST CANCER
  • 7.3. LUNG CANCER
  • 7.4. COLORECTAL CANCER
  • 7.5. PROSTATE CANCER
  • 7.6. MELANOMA CANCER
  • 7.7. OTHERS CANCER

8. CANCER/TUMOR PROFILING MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. CLINICAL APPLICATION
  • 8.3. RESEARCH APPLICATION

9. CANCER/TUMOR PROFILING MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
  • 9.4. ASIA-PACIFIC
  • 9.5. REST OF THE WORLD (ROW)

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. BATTLE FOR MARKET SHARE: PRODUCT LAUNCH WAS THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS BETWEEN 2013 AND 2016
  • 10.3. PRODUCT LAUNCHES
  • 10.4. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
  • 10.5. ACQUISITIONS
  • 10.6. OTHERS STRATEGIES

11. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 11.1. INTRODUCTION
  • 11.2. ILLUMINA, INC.
  • 11.3. QIAGEN N.V.
  • 11.4. NEOGENOMICS LABORATORIES, INC.
  • 11.5. HTG MOLECULAR DIAGNOSTICS, INC.
  • 11.6. GENOMIC HEALTH INC.
  • 11.7. CARIS LIFE SCIENCES
  • 11.8. HELOMICS CORPORATION
  • 11.9. NANOSTRING TECHNOLOGIES, INC.
  • 11.10. OXFORD GENE TECHNOLOGY
  • 11.11. RIBOMED BIOTECHNOLOGIES, INC.

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. OTHER DEVELOPMENTS
  • 12.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.6. AVAILABLE CUSTOMIZATIONS
  • 12.7. RELATED REPORTS
  • 12.8. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
  • TABLE 2: NATIONAL INSTITUTES OF HEALTH (NIH) SPENDING, BY TYPE OF CANCER (FINANCIAL YEAR 2015)
  • TABLE 3: CANCER/TUMOR PROFILING MARKET SIZE, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 4: HYBRIDIZATION MARKET FOR CANCER/TUMOR PROFILING, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 5: GLOBAL IMMUNOASSAYS MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 6: NORTH AMERICA: IMMUNOASSAYS MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 7: GLOBAL HYBRIDIZATION MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 8: NORTH AMERICA: HYBRIDIZATION MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 9: GLOBAL PCR MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 10: NORTH AMERICA: PCR MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 11: GLOBAL IN SITU HYBRIDIZATION MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 12: NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 13: GLOBAL DNA/RNA MICROARRAY MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 14: NORTH AMERICA: DNA/RNA MICROARRAY MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 15: GLOBAL NEXT-GENERATION SEQUENCING MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 16: NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 17: GLOBAL MASS SPECTROMETRY MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 18: NORTH AMERICA: MASS SPECTROMETRY MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 19: GLOBAL OTHER TECHNOLOGIES MARKET FOR CANCER/TUMOR PROFILING, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 20: NORTH AMERICA: OTHER TECHNOLOGIES MARKET FOR CANCER/TUMOR PROFILING, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 21: GLOBAL CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 22: GLOBAL BREAST CANCER/TUMOR PROFILING MARKET SIZE, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 23: NORTH AMERICA BREAST CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 24: GLOBAL LUNG CANCER/TUMOR PROFILING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 25: NORTH AMERICA LUNG CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 26: GLOBAL COLORECTAL CANCER/TUMOR PROFILING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 27: NORTH AMERICA COLORECTAL CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 28: GLOBAL PROSTATE CANCER/TUMOR PROFILING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 29: GLOBAL MELANOM CANCER/TUMOR PROFILING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 30: NORTH AMERICA MELANOMA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 31: GLOBAL OTHER TYPE OF CANCER/TUMOR PROFILING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 32: NORTH AMERICA OTHER TYPE OF CANCER/TUMOR PROFILING MARKET BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 33: CANCER/TUMOR PROFILING MARKET SIZE, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 34: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 35: NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 36: CANCER/TUMOR PROFILING MARKET FOR RESAERCH APPLICATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 37: NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESAERCH APPLICATION, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 38: GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 39: NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2015-2022 (USD MILLION)
  • TABLE 40: NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SIZE, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 41: NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 42: NORTH AMERICA: HYBRIDIZATION TECHNOLOGY MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 43: NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 44: US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 45: US: HYBRIDIZATION TECHNOLOGY MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 46: US: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 47: US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 48: CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 49: CANADA: HYBRIDIZATION TECHNOLOGY MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 50: CANADA: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 51: CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 52: EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 53: EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 54: EUROPE: HYBRIDIZATION TECHNOLOGY MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 55: EUROPE: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 56: ASIA-PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 57: ASIA-PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 58: ASIA-PACIFIC: HYBRIDIZATION TECHNOLOGY MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 59: ASIA-PACIFIC: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 60: ROW: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2015-2022 (USD MILLION)
  • TABLE 61: ROW: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
  • TABLE 62: ROW: HYBRIDIZATION TECHNOLOGY MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 63: ROW: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2015-2022 (USD MILLION)
  • TABLE 64: PRODUCT LAUNCHES, 2013-2016
  • TABLE 65: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013-2016
  • TABLE 66: ACQUISITIONS, 2013-2016
  • TABLE 67: OTHER STRATEGIES, 2013-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: CANCER/TUMOR PROFILING MARKET TOP DOWN APPROACH
  • FIGURE 3: CANCER/TUMOR PROFILING MARKET: BOTTOM UP APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: MARKET DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES: 2000 VS. 2014
  • FIGURE 7: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017 VS. 2022 (USD MILLION)
  • FIGURE 8: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017 VS. 2022 (USD MILLION)
  • FIGURE 9: CANCER/TUMOR PROFILING MARKET, BY HYBRIDIZATION TECHNOLOGY, 2017 VS. 2022 (USD MILLION)
  • FIGURE 10: CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2017 VS. 2022 (USD MILLION)
  • FIGURE 11: GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET
  • FIGURE 12: TECHNOLOGY ADVANCEMENT IS A MAJOR DRIVER FOR THE CANCER/TUMOR PROFILING MARKET GROWTH IN 2017
  • FIGURE 13: CLINICAL APPLICATION WILL CONTINUE TO DOMINATE THE CANCER/TUMOR PROFILING MARKET IN 2022
  • FIGURE 14: PCR IS EXPECTED TO BE THE FASTEST GROWING SEGMENT DURING FORECAST PERIOD
  • FIGURE 15: APAC WILL BE THE FASTEST-GROWING MARKET FROM 2017 TO 2022
  • FIGURE 16: CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE (2012 VS. 2015 VS. 2020)
  • FIGURE 18: NEW CANCER CASES, BY COUNTRY (2012)
  • FIGURE 19: NEW CANCER CASES, BY COUNTRY (2020)
  • FIGURE 20: IMMUNOASSAYS SEGMENT TO DOMINATE THE MARKET IN THE FORECAST PERIOD
  • FIGURE 21: CLINICAL APPLICATION SEGMENT TO DOMINATE THE MARKET IN THE FORECAST PERIOD
  • FIGURE 22: CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2017-2022)
  • FIGURE 23: NORTH AMERICA MARKET SNAPSHOT
  • FIGURE 24: ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SNAPSHOT
  • FIGURE 25: COMPANIES MAJORLY PURSUED THE STRATEGY OF PRODUCT LAUNCH BETWEEN 2013 AND 2016
  • FIGURE 26: GEOGRAPHIC REVENUE MIX OF THE PROMINENT PLAYERS IN THE CANCER/TUMOR PROFILING MARKET
  • FIGURE 27: COMPANY SNAPSHOT: ILLUMINA, INC.
  • FIGURE 28: COMPANY SNAPSHOT: QIAGEN N.V.
  • FIGURE 29: COMPANY SNAPSHOT: NEOGENOMICS LABORATORIES, INC.
  • FIGURE 30: COMPANY SNAPSHOT: HTG MOLECULAR DIAGNOSTICS, INC.
  • FIGURE 31: COMPANY SNAPSHOT: GENOMIC HEALTH INC.
  • FIGURE 32: COMPANY SNAPSHOT: NANOSTRING TECHNOLOGIES, INC.
Back to Top